Association between HLA-A1 and -A2 types and Epstein–Barr virus status of post-transplant lymphoproliferative disorder

References

• Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of haemotopoietic and lymphoid tissue. 4th ed. Lyon: IARC; 2008. p. 343–350.
   Google Scholar
• Jagadeesh D, Woda BA, Draper J, et al. Post-transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol. 2012;13:122–136.
   PubMed Web of Science ®Google Scholar
• Kinch A, Baecklund E, Backlin C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein–Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 2014;53:669–679.
   PubMed Web of Science ®Google Scholar
• Caillard S, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant. 2012;12:682–693.
   PubMed Web of Science ®Google Scholar
• Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol. 2011;86:206–209.
   PubMed Web of Science ®Google Scholar
• Herreman A, Dierickx D, Morscio J, et al. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma. 2013;54:2190–2199.
   PubMed Web of Science ®Google Scholar
• Reshef R, Luskin MR, Kamoun M, et al. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant. 2011;11:817–825.
   PubMed Web of Science ®Google Scholar
• Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation. 2006;82:1093–1100.
   PubMed Web of Science ®Google Scholar
• Lustberg ME, Pelletier RP, Porcu P, et al. Human leukocyte antigen type and posttransplant lymphoproliferative disorder. Transplantation. 2015;99:1220–1225.
   PubMed Web of Science ®Google Scholar
• Pourfarziani V, Einollahi B, Taheri S, et al. Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant. 2007;12:16–22.
   PubMed Web of Science ®Google Scholar
• Wheless SA, Gulley ML, Raab-Traub N, et al. Post-transplantation lymphoproliferative disease: Epstein–Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med. 2008;178:1060–1065.
   PubMed Web of Science ®Google Scholar
• Jones K, Wockner L, Thornton A, et al. HLA class I associations with EBV + post-transplant lymphoproliferative disorder. Transpl Immunol. 2015;32:126–130.
   PubMed Web of Science ®Google Scholar
• Hjalgrim H, Rostgaard K, Johnson PC, et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci USA. 2010;107:6400–6405.
   PubMed Web of Science ®Google Scholar
• Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV + Hodgkin lymphoma. Blood. 2007;110:3310–3315.
   PubMed Web of Science ®Google Scholar
• Huang X, Kushekhar K, Nolte I, et al. HLA associations in classical Hodgkin lymphoma: EBV status matters. PLoS One. 2012;7:e39986
   PubMed Web of Science ®Google Scholar
• Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein–Barr virus-associated diseases. Annu Rev Microbiol. 2000;54:19–48.
   PubMed Web of Science ®Google Scholar
• Hislop AD, Taylor GS, Sauce D, et al. Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol. 2007;25:587–617.
   PubMed Web of Science ®Google Scholar
• Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.
   PubMed Web of Science ®Google Scholar
• Straathof KC, Leen AM, Buza EL, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005;175:4137–4147.
   PubMed Web of Science ®Google Scholar
• San-Juan R, Comoli P, Caillard S, et al. Epstein–Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 2014;20:109–118.
   PubMed Web of Science ®Google Scholar
• Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262–274.
   PubMed Web of Science ®Google Scholar
• Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5:2222–2228.
   PubMed Web of Science ®Google Scholar
• Martin SI, Dodson B, Wheeler C, et al. Monitoring infection with Epstein–Barr virus among seromismatch adult renal transplant recipients. Am J Transplant. 2011;11:1058–1063.
   PubMed Web of Science ®Google Scholar
• Klintmalm GB, Saab S, Hong JC, et al. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clin Transplant. 2014;28:635–648.
   PubMed Web of Science ®Google Scholar
• Alcoceba M, Sebastian E, Marin L, et al. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood. 2013;122:1448–1454.
   PubMed Web of Science ®Google Scholar